This performance was driven by sustained demand for therapies targeting serious conditions, particularly Xolair (chronic hives, food allergies), Phesgo (breast cancer), Hemlibra (haemophilia A), Vabysmo (severe eye diseases), and Ocrevus (multiple sclerosis)
Each treatment is customized to address the unique needs of our clients, ensuring optimal results
Our consensus group recommends considering telemedicine evaluation at 1 month to verify the correct management of KDT, and after the first year of KDT as an alternative option, with follow-up on a 6-month basis beyond yearly onsite follow-up
When Fatigue on Semaglutide Signals a Bigger Problem While mild to moderate fatigue is expected early in semaglutide treatment, severe fatigue that limits your ability to work, exercise, or care for yourself warrants immediate attention